biostudies-literatureUnknown9(1)Camus V<h4>Abstract</h4>There is a scarcity of data on the tumor B-cell receptor (BCR) repertoire and lymphoid microenvironment in primary mediastinal B-cell lymphoma (PMBL). We applied 5' rapid amplification of complimentary DNA ends (5'RACE) to tumor RNA samples from 137 patients with PMBL with available gene expression profiling and next-generation sequencing data. We obtained 5'RACE results for 75 of the 137 (54.7%) patients with the following clinical characteristics: median age (range), 33 years (18-64); female, 53.3%; performance status score 0 to 1, 86.7%; stage I to II, 57.3%; first-line treatment with anti-CD20 plus doxorubicin-based chemotherapy, 100%. Among the 60 biopsies that expressed a productive BCR, we highlighted a strong somatic hypermutation profile, defined as <98% identity Blood advances101-115https://www.ebi.ac.uk/biostudies/studies/S-EPMC11742575biostudies-literatureIdentification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5'RACE.PMC11742575Decazes PVeresezan ELBayaram MGower NKaltenbach SRainville VBecker SViailly PJBohers EBruneau JWillaume AGaulard PAntier CLeveque EMartin LDrieux FJardin FRossi CTournilhac OViennot MDurot ESesques PMolina TJHaioun CPaillassa JRuminy PTilly HBobee VDonzel MRenaud LTonnelet DPenther DTraverse-Glehen ACamus VfalseIdentification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5'RACE.<h4>Abstract</h4>There is a scarcity of data on the tumor B-cell receptor (BCR) repertoire and lymphoid microenvironment in primary mediastinal B-cell lymphoma (PMBL). We applied 5' rapid amplification of complimentary DNA ends (5'RACE) to tumor RNA samples from 137 patients with PMBL with available gene expression profiling and next-generation sequencing data. We obtained 5'RACE results for 75 of the 137 (54.7%) patients with the following clinical characteristics: median age (range), 33 years (18-64); female, 53.3%; performance status score 0 to 1, 86.7%; stage I to II, 57.3%; first-line treatment with anti-CD20 plus doxorubicin-based chemotherapy, 100%. Among the 60 biopsies that expressed a productive BCR, we highlighted a strong somatic hypermutation profile, defined as <98% identity 2025-01-01T00:00:00Z2025 Jan2025-04-22T05:25:05.459Z2025-04-05T21:20:31.936ZS-EPMC117425753929308010.1182/bloodadvances.2024013723